Literature DB >> 25473753

Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence?

Ira Winer1, Quratulain F Ahmed, Ismail Mert, Sudeshna Bandyopadhyay, Michele Cote, Adnan R Munkarah, Yaser Hussein, Zaid Al-Wahab, Mohamed A Elshaikh, Baraa Alosh, Daniel S Schultz, Haider Mahdi, Marisa R Nucci, Koen K Van de Vijver, Robert T Morris, Esther Oliva, Rouba Ali-Fehmi.   

Abstract

To analyze the clinical significance of the extent of lymphovascular space invasion (LVI) in patients with uterine serous carcinoma. After IRB approval, 232 patients with uterine serous carcinoma from the pathology databases of 4 large academic institutions were included. Patients were divided into 3 groups based on extent of LVI. Extensive LVI (E-LVI) was defined as ≥3 vessel involvement; low LVI (L-LVI) was defined <3 vessel involvement; and the third group consisted of tumors with no LVI (A-LVI). The association between LVI and myometrial invasion, cervical involvement, lower uterine segment involvement, positive peritoneal washings, lymph node involvement, stage, and survival were analyzed. Of 232 patients, 47 had E-LVI (20.3%), 83 had L-LVI (35.8%), and 102 had A-LVI (44%). A total of 9.8% of the patients with A-LVI had lymph node involvement as compared with 18.1% in the L-LVI group and 55.4% in the E-LVI group (P<0.0001). Fifty-nine percent of the patients in A-LVI, 85% in L-LVI, and 100% in the E-LVI group demonstrated myometrial invasion (P<0.0001). Cervical involvement was noted in 23%, 43%, 66% (P<0.0001) and lower uterine segment involvement involvement in 31%, 43%, and 42% of A-LVI, L-LVI, and E-LVI (P<0.0001), respectively. Stage III and IV disease were seen in 29%, 38%, and 79% of the patients with A-LVI, L-LVI, and E-LVI, respectively (P<0.0001). The median overall survival was 172, 95, and 39 mo for the A-LVI, L-LVI, and E-LVI groups, respectively (P<0.0001). The racial distribution was significant with African American patients demonstrating significantly more L-LVI (27.8%) and E-LVI (40.4%) when compared with A-LVI (19.6%) (P=0.040). In a subgroup analysis including patients with Stage I and II (n=123) revealed median survivals of 172, 169, and 38 mo in the A-LVI, L-LVI, and E-LVI groups, respectively (P<0.0001). Fifty percent of these patients with E-LVI, 20% in L-LVI group, and 15% in A-LVI group had disease recurrence (P=0.040). The extent of LVI was associated with multiple pathologic factors and was found to be a negative prognostic factor for overall survival and disease recurrence.

Entities:  

Mesh:

Year:  2015        PMID: 25473753     DOI: 10.1097/PGP.0000000000000113

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  9 in total

1.  Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.

Authors:  A Stiekema; Car Lok; C M Korse; W J van Driel; V van der Noort; G G Kenter; K K Van de Vijver
Journal:  Virchows Arch       Date:  2017-04-11       Impact factor: 4.064

Review 2.  Practical issues in the diagnosis of serous carcinoma of the endometrium.

Authors:  Sonia Gatius; Xavier Matias-Guiu
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

3.  Cancer of the corpus uteri: 2021 update.

Authors:  Martin Koskas; Frédéric Amant; Mansoor Raza Mirza; Carien L Creutzberg
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

4.  Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases.

Authors:  Yao Wang; Mei Yu; Jia-Xin Yang; Dong-Yan Cao; Keng Shen; Jing-He Lang
Journal:  Cancer Manag Res       Date:  2018-10-25       Impact factor: 3.989

5.  Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in lymph node metastases and risk stratification of endometrial carcinoma.

Authors:  Dou Dou Liu; Jianfang Li; Xiaomao Li; Liangjun Xie; Luping Qin; Fangyu Peng; Mu Hua Cheng
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

6.  Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer.

Authors:  Elke E M Peters; Carla Bartosch; W Glenn McCluggage; Catherine Genestie; Sigurd F Lax; Remi Nout; Jan Oosting; Naveena Singh; Huub C S H Smit; Vincent T H B M Smit; Koen K Van de Vijver; Tjalling Bosse
Journal:  Histopathology       Date:  2019-06-10       Impact factor: 5.087

Review 7.  Incorporation of molecular characteristics into endometrial cancer management.

Authors:  Lisa Vermij; Vincent Smit; Remi Nout; Tjalling Bosse
Journal:  Histopathology       Date:  2020-01       Impact factor: 5.087

Review 8.  Tumor Staging of Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists.

Authors:  Kay J Park; Andres Roma; Naveena Singh; C Blake Gilks; Esther Oliva; Nadeem Abu-Rustum; Pedro T Ramirez; W Glenn McCluggage
Journal:  Int J Gynecol Pathol       Date:  2021-03-01       Impact factor: 3.326

9.  PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance.

Authors:  Tao Zhang; Qin Liu; Yingfan Zhu; Songfa Zhang; Qiaohua Peng; Amanda Louise Strickland; Wenxin Zheng; Feng Zhou
Journal:  Cancer Manag Res       Date:  2021-12-14       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.